Volv Global personalises healthcare by providing insights on patients and diseases powered by data-driven AI and machine learning.
Our custom, proprietary, machine learning algorithms power a suite of services for pharmaceutical companies that reduces costs throughout the healthcare ecosystem and improves outcomes for those living with disease.
Stratify and triage patients for individualised and optimised treatment, saving time, cost and the emotional burden of incorrect diagnosis.
Characterise, segment and target patient cohorts to make clinical development and commercialisation more efficient and cost-effective.
Generate novel insights and new understanding of patient biomarkers, phenotypes, clinical features and endpoints.
Optimise resource allocation and reduce cost impact of incorrect or late diagnoses, while maximising quality of life and outcomes.
Volv Global helps you work smarter
Volv Global uses AI and population-scale data to generate knowledge and insights into difficult-to-diagnose diseases that others cannot match. Our clients can leverage these insights to enhance clinical development strategies, enrich disease understanding, and gain an edge over their rivals. Our insights help identify opportunities to rapidly develop diagnostic tools, reposition existing drugs that increase R&D viability, so our clients can target new markets, work smarter and drive profitability.
Volv Global, in numbers
Volv Global delivers high-value solutions at speed
De-risk clinical strategy & improve robustness of trial planning.
Generate meaningful and valuable real-world evidence.
Expand the boundaries of medical understanding with new RWD insights.
Launch strongly and extend the product lifecycle by finding more patients.
Driving Innovation in Rare Disease & Healthcare AI
At Volv Global, we combine advanced AI in healthcare with real-world data (RWD) to deliver transformative solutions for rare and difficult-to-diagnose disease patients. Our proprietary methodology for machine learning in healthcare technology enables:
– Detecting rare diseases faster and more accurately
– Generating real-world evidence (RWE) for clinical trials and regulatory submissions
– Optimising the patient journey with data-driven insights
– Reducing time and costs in drug development and market access
By partnering with Volv Global, pharmaceutical innovators, healthcare providers, and policymakers gain the tools to make smarter, faster, and more impactful decisions across the entire healthcare ecosystem.
Introducing inTrigue
With inTrigue, our flagship machine learning methodology, Volv Global transforms disease management and treatment at the individual patient level, along the patient journey and optimising patient outcomes.
Understanding patient phenomenology, across all diseases.
We ensure that all patients are offered the right treatment options and increase the pool of RWD on a disease.
We detect subtle patterns among biomarkers to predict disease incidence early, sometimes years ahead of time.
We model disease progression and are able to provide prognoses, instead of diagnoses.
We detect, cluster and differentiate sub-groups within a heterogenous patient cohort, to learn more about disease pathways.
The human story
Volv Global helps transform lives by giving pharmaceutical innovators powerful insights into difficult-to-diagnose diseases so they can develop effective tools and treatments. To the patient this might look like earlier diagnosis, a lifechanging drug or the opportunity to connect with a wider community for education and support as they navigate life with a rare disease.
Stay informed
A prediction model to identify symptomatic patients of different races and ethnicities with risk of Alpha-1 Antitryps...
New research demonstrates that machine learning can map clinician-defined endpoints to real-world claims data in Pomp...
Volv Global joins Tech Tour Growth Health 2026 in Lausanne, 30 June – 1 July, connecting with Europe's leading health...
Volv Global joins Innovaud, One Nucleus & ARC West London to explore innovation and investment opportunities acro...
When science fiction becomes science fact: AI for rare disease diagnosis – how Volv Global's work moves us from the i...
Repeated steroid use in IBD care signals failing treatment pathways. Learn why steroid exposure is a key red flag and...
Discover how patient advocacy accelerates rare disease diagnosis and innovation, bringing technology, real-world data...
Guest article by Rareatives reflecting on Rare Disease Day and why awareness, patient stories, and advocacy play a vi...
Explore why diagnostic delays in cancer remain a major challenge and how earlier diagnosis, better data, and healthca...
Discover how data-driven insights help identify undiagnosed rare disease patients earlier and close the diagnostic ga...
Volv Global will be exhibiting at Faces of Industrial Research (FIR) 2026 on Friday, February 20th, 2026, at the EPFL...
Explore a podcast on rare disease diagnosis, diagnostic delays, and how AI innovation can shorten the path from sympt...
Go deeper
A prediction model to identify symptomatic patients of different races and ethnicities with risk of Alpha-1 Antitryps...
New research demonstrates that machine learning can map clinician-defined endpoints to real-world claims data in Pomp...
Repeated steroid use in IBD care signals failing treatment pathways. Learn why steroid exposure is a key red flag and...
Discover how patient advocacy accelerates rare disease diagnosis and innovation, bringing technology, real-world data...
Explore why diagnostic delays in cancer remain a major challenge and how earlier diagnosis, better data, and healthca...
Discover how data-driven insights help identify undiagnosed rare disease patients earlier and close the diagnostic ga...
Explore a podcast on rare disease diagnosis, diagnostic delays, and how AI innovation can shorten the path from sympt...
Chronic Obstructive Pulmonary Disease remains under-recognised & under-diagnosed. How do we ensure COPD patients ...
MASH/NASH: Why Therapeutic Breakthroughs Demand a New Era of Patient Identification. Novel therapies only achieve the...
Bridging gaps across the CLL care pathway, Part 2: Knowing When To Treat – AI for Transformation, Infection Risk, and...
Bridging gaps across the CLL care pathway, Part 1: From Signal to Stratification – Reimagining Early CLL Care through...
The next multiple myeloma frontier is the creation of AI-driven diagnostic systems that recognise this cancer sooner ...
